JP2020158493A - Water-in-oil type (w/o type) cream containing panthenol - Google Patents
Water-in-oil type (w/o type) cream containing panthenol Download PDFInfo
- Publication number
- JP2020158493A JP2020158493A JP2020047463A JP2020047463A JP2020158493A JP 2020158493 A JP2020158493 A JP 2020158493A JP 2020047463 A JP2020047463 A JP 2020047463A JP 2020047463 A JP2020047463 A JP 2020047463A JP 2020158493 A JP2020158493 A JP 2020158493A
- Authority
- JP
- Japan
- Prior art keywords
- water
- panthenol
- oil
- type
- emulsified composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 title claims abstract description 78
- 229940101267 panthenol Drugs 0.000 title claims abstract description 71
- 239000011619 pantothenol Substances 0.000 title claims abstract description 71
- 235000020957 pantothenol Nutrition 0.000 title claims abstract description 71
- 239000006071 cream Substances 0.000 title description 18
- 239000000203 mixture Substances 0.000 claims abstract description 45
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229940046009 vitamin E Drugs 0.000 claims abstract description 7
- 239000011709 vitamin E Substances 0.000 claims abstract description 7
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims description 20
- 229920001499 Heparinoid Polymers 0.000 claims description 14
- 239000002554 heparinoid Substances 0.000 claims description 14
- 229940088594 vitamin Drugs 0.000 claims description 9
- 229930003231 vitamin Natural products 0.000 claims description 9
- 235000013343 vitamin Nutrition 0.000 claims description 9
- 239000011782 vitamin Substances 0.000 claims description 9
- -1 acetyl panthenyl ethyl ether Chemical compound 0.000 claims description 8
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 8
- 230000001804 emulsifying effect Effects 0.000 claims description 6
- 229940025770 heparinoids Drugs 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 claims description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 3
- 229960002079 calcium pantothenate Drugs 0.000 claims description 3
- 229940023735 panthenyl ethyl ether Drugs 0.000 claims description 3
- GQTHJBOWLPZUOI-FJXQXJEOSA-M sodium D-pantothenate Chemical compound [Na+].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GQTHJBOWLPZUOI-FJXQXJEOSA-M 0.000 claims description 3
- 229940068459 sodium pantothenate Drugs 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 11
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 6
- 239000000839 emulsion Substances 0.000 abstract description 4
- 206010013786 Dry skin Diseases 0.000 abstract description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract description 2
- 239000002628 heparin derivative Substances 0.000 abstract description 2
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 35
- 210000003491 skin Anatomy 0.000 description 23
- 230000003020 moisturizing effect Effects 0.000 description 22
- 239000008308 lipophilic cream Substances 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Polymers FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 11
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 11
- 229940042585 tocopherol acetate Drugs 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 10
- 210000000434 stratum corneum Anatomy 0.000 description 10
- 238000000034 method Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000008309 hydrophilic cream Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000004866 D-panthenol Nutrition 0.000 description 3
- 239000011703 D-panthenol Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000021470 vitamin B5 (pantothenic acid) Nutrition 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010059516 Skin toxicity Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229940038727 mucopolysaccharide polysulfate Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、パンテノールを含有する皮膚外用塗布剤に関し、特に乾燥肌や肌荒れの改善のために用いる皮膚外用塗布剤に関する。 The present invention relates to an external application for skin containing panthenol, and more particularly to an external application for skin used for improving dry skin and rough skin.
パンテノールは、体内でビタミンB5(パントテン酸)に変換されるプロビタミンB5とも呼ばれる水溶性のプロビタミンであり、皮膚組織修復作用や抗炎症効果、保湿作用などを有するとされることから、乾燥等による肌荒れの改善を目的として、乳液やクリームなど、化粧品等に配合されている。 Panthenol is a water-soluble provitamin, also called provitamin B5, which is converted to vitamin B5 (pantothenic acid) in the body, and is said to have skin tissue repairing, anti-inflammatory, and moisturizing effects. It is added to cosmetics such as milky lotion and cream for the purpose of improving rough skin caused by.
パンテノールは、皮膚刺激性や毒性がほとんど報告されておらず、安全性の高い成分と考えられている。そのため、様々な軟膏やクリームに配合されてきた(特許文献1、特許文献2)。しかし、その作用が緩和で、即効性はなく、効果を得るには長期間にわたって毎日塗り続ける必要があった。 Panthenol is considered to be a highly safe ingredient with few reports of skin irritation or toxicity. Therefore, it has been blended in various ointments and creams (Patent Document 1 and Patent Document 2). However, its action was mild and had no immediate effect, and it was necessary to continue applying it daily for a long period of time to obtain the effect.
パンテノールの皮膚組織修復作用や抗炎症効果、保湿作用を、従来よりも短期間の塗布で得ることを課題とする。 An object of the present invention is to obtain the skin tissue repairing effect, anti-inflammatory effect, and moisturizing effect of panthenol by application in a shorter period of time than before.
パンテノールを油中水型乳化組成物に含有させて、これを皮膚に塗布することで、短時間で優れた保湿効果を発揮することを見出した。 It has been found that panthenol is contained in a water-in-oil emulsified composition and applied to the skin to exhibit an excellent moisturizing effect in a short time.
さらに、油中水型乳化組成物とした場合、保湿や肌荒れ改善を目的に使用されるヘパリン類似物質及びビタミンE類と併用した場合にも、パンテノールは優れた保湿効果を発揮することを見出した。 Furthermore, it was found that panthenol exerts an excellent moisturizing effect when used in combination with a heparinoid and vitamin E used for moisturizing and improving rough skin when used as a water-in-oil emulsified composition. It was.
より具体的には、本件出願は、前述した課題を解決するため、以下の態様を提供する:
[1]:パンテノールまたはパンテノール類縁物質を含有する、油中水型(W/O型)乳化組成物;
[2]:パンテノールまたはパンテノール類縁物質の含有量が0.5〜5.0質量%である、[1]に記載の油中水型(W/O型)乳化組成物;
[3]:パンテノール類縁物質が、パントテニルエチルエーテル、パントテン酸カルシウム、パントテン酸ナトリウム、およびアセチルパンテニルエチルエーテルからなる群から選択される、[1]または[2]に記載の油中水型(W/O型)乳化組成物;
[4]:親油性乳化剤としてグリセリン脂肪酸エステルを含有する、[1]〜[3]のいずれか1項に記載の油中水型(W/O型)乳化組成物;
[5]:ヘパリン類似物質、ビタミンE類、またはヘパリン類似物質及びビタミンE類をさらに含有する、[1]〜[4]のいずれか1項に記載の油中水型(W/O型)乳化組成物;
[6]:ヘパリン類似物質の含有量が0.1〜0.5質量%、またはビタミンE類の含有量が0.5〜2.0質量%である、[5]に記載の油中水型(W/O型)乳化組成物;
[7]:皮膚外用塗布に用いる、[1]〜[6]のいずれか1項に記載の油中水型(W/O型)乳化組成物;
[8]:[1]〜[6]のいずれか1項に記載の油中水型(W/O型)乳化組成物である、皮膚外用塗布剤。
More specifically, the present application provides the following aspects in order to solve the above-mentioned problems:
[1]: Water-in-oil (W / O type) emulsified composition containing panthenol or a panthenol-related substance;
[2]: The water-in-oil (W / O type) emulsified composition according to [1], wherein the content of panthenol or a panthenol-related substance is 0.5 to 5.0% by mass;
[3]: The water in oil according to [1] or [2], wherein the panthenol-related substance is selected from the group consisting of pantothenyl ethyl ether, calcium pantothenate, sodium pantothenate, and acetyl panthenyl ethyl ether. Type (W / O type) emulsified composition;
[4]: The water-in-oil (W / O type) emulsified composition according to any one of [1] to [3], which contains a glycerin fatty acid ester as a lipophilic emulsifier;
[5]: The water-in-oil type (W / O type) according to any one of [1] to [4], which further contains heparinoids, vitamin Es, or heparinoids and vitamin Es. Emulsified composition;
[6]: Water-in-oil (W / O type) emulsification according to [5], wherein the content of heparinoids is 0.1 to 0.5% by mass, or the content of vitamin Es is 0.5 to 2.0% by mass. Composition;
[7]: The water-in-oil (W / O type) emulsified composition according to any one of [1] to [6] used for external application to the skin;
[8]: A coating agent for external use on the skin, which is a water-in-oil (W / O type) emulsifying composition according to any one of [1] to [6].
パンテノールを油中水型乳化組成物に含有させて、これを皮膚に塗布することで、短時間で優れた保湿効果を発揮することができる。さらに、油中水型乳化組成物とした場合、保湿や肌荒れ改善を目的に使用されるヘパリン類似物質及びビタミンE類と併用した場合にも、パンテノールは優れた保湿効果は発揮することができる。 By incorporating panthenol in a water-in-oil emulsified composition and applying it to the skin, an excellent moisturizing effect can be exhibited in a short time. Furthermore, when a water-in-oil emulsified composition is used, panthenol can exert an excellent moisturizing effect even when used in combination with a heparinoid and vitamin E used for the purpose of moisturizing and improving rough skin. ..
本発明者らは、パンテノール(D-パントテニルアルコール)またはパンテノール類縁物質を、油中水型(W/O型)乳化組成物に含有させたところ、皮膚に塗布した場合に短時間で優れた保湿効果を発揮することを見出したことにより、本発明を完成させるに至った。 The present inventors added panthenol (D-panthenol alcohol) or a panthenol-related substance to a water-in-oil (W / O type) emulsifying composition, and when applied to the skin, in a short time. The present invention has been completed by finding that it exhibits an excellent moisturizing effect.
この知見に基づき、本発明は、パンテノールまたはパンテノール類縁物質を有効成分として含有する、油中水型(W/O型)乳化組成物を提供する。 Based on this finding, the present invention provides a water-in-oil (W / O type) emulsified composition containing panthenol or a panthenol-related substance as an active ingredient.
パンテノールは、体内でビタミンB5(パントテン酸)に変換されるプロビタミンB5とも呼ばれる水溶性のプロビタミンであり、保湿作用、組織修復促進作用、抗炎症作用を有することが知られている。 Panthenol is a water-soluble provitamin also called provitamin B5 that is converted to vitamin B5 (pantothenic acid) in the body, and is known to have a moisturizing effect, a tissue repair promoting effect, and an anti-inflammatory effect.
パンテノール類縁物質は、生体内でパンテノールと同様の活性を有するパンテノールの誘導体物質群であり、パントテニルエチルエーテル、パントテン酸カルシウム、パントテン酸ナトリウム、アセチルパンテニルエチルエーテルなどが含まれるが、これらに限定されない。 Panthenol-related substances are a group of derivative substances of panthenol having the same activity as panthenol in vivo, and include pantothenyl ethyl ether, calcium pantothenate, sodium pantothenate, acetyl panthenyl ethyl ether, and the like. Not limited to these.
本発明においては、パンテノールまたはパンテノール類縁物質を、油中水型(W/O型)乳化組成物とすることを特徴とする。より具体的には、本発明の油中水型(W/O型)乳化組成物は、油状成分の中に、パンテノールまたはパンテノール類縁物質を溶解した水性成分の液滴を分散させたものである。 The present invention is characterized in that panthenol or a panthenol-related substance is used as a water-in-oil (W / O type) emulsified composition. More specifically, the water-in-oil (W / O type) emulsified composition of the present invention is obtained by dispersing droplets of an aqueous component in which panthenol or a panthenol-related substance is dissolved in an oil component. Is.
本発明において、パンテノールまたはパンテノール類縁物質を油中水型(W/O型)乳化組成物中に分散させるためには、油状成分中に水性成分を分散させる必要があることから、この目的のためには、HLB値(Hydrophilic-Lipophilic Balance)が3から8程度の、より好ましくは3から6程度の界面活性剤が親油性乳化剤として使用される。そのような親油性乳化剤(親油性の非イオン界面活性剤)の例としては、グリセリン脂肪酸エステル、モノオレイン酸ソルビタン、セスキオレイン酸ソルビタン、ポリオキシエチレン硬化ヒマシ油などが含まれる。グリセリン脂肪酸エステルの例としては、モノオレイン酸ポリグリセリル、モノステアリン酸ポリグリセリル、モノイソステアリン酸ポリグリセリル、ペンタイソステアリン酸ポリグリセリル、ペンタオレイン酸ポリグリセリルなどが含まれる。油中水型クリームの製造方法は、当該技術分野において周知であり、例えば、油相を撹拌しながら水を添加する方法などが知られているが、この他の当該技術分野において周知な方法(例えば、「新 化粧品ハンドブック」に記載の方法など)に従って製造してもよい。 In the present invention, in order to disperse pantenol or a pantenol-related substance in a hydrophilic (W / O type) emulsifying composition, it is necessary to disperse an aqueous component in an oil component. For this purpose, a surfactant having an HLB value (Hydrophilic-Lipophilic Balance) of about 3 to 8, more preferably about 3 to 6, is used as a lipophilic emulsifier. Examples of such lipophilic emulsifiers (lipophilic nonionic surfactants) include glycerin fatty acid esters, sorbitan monooleate, sorbitan sesquioleate, polyoxyethylene hydrogenated castor oil and the like. Examples of glycerin fatty acid esters include polyglyceryl monooleate, polyglyceryl monostearate, polyglyceryl monoisostearate, polyglyceryl pentaisostearate, polyglyceryl pentaoleate and the like. A method for producing a water-in-oil cream is well known in the art, for example, a method of adding water while stirring the oil phase is known, but other methods well known in the art ( For example, it may be manufactured according to the method described in the "New Cosmetics Handbook").
本発明の油中水型(W/O型)乳化組成物中における、パンテノールまたはパンテノール類縁物質の含有量は、0.1〜8.0質量%、より好ましくは0.5〜5.0質量%であり、さらに好ましくは1.0〜3.0質量%である。 The content of panthenol or a panthenol-related substance in the water-in-oil (W / O type) emulsified composition of the present invention is 0.1 to 8.0% by mass, more preferably 0.5 to 5.0% by mass, further preferably. Is 1.0 to 3.0% by mass.
本発明の油中水型(W/O型)乳化組成物は、保湿作用、組織修復促進作用、抗炎症作用を発揮させることを目的としていることから、パンテノール以外に保湿作用、組織修復促進作用、抗炎症作用を有する有効成分をさらに含有していてもよい。本発明の油中水型(W/O型)乳化組成物に含有させることができるさらなる有効成分としては、例えば、ヘパリン類似物質や、ビタミンE類、などから選択される1または複数種の成分を使用することができる。 Since the water-in-oil (W / O type) emulsifying composition of the present invention is intended to exert a moisturizing action, a tissue repair promoting action, and an anti-inflammatory action, it has a moisturizing action and a tissue repair promoting action in addition to panthenol. It may further contain an active ingredient having an action and an anti-inflammatory action. As a further active ingredient that can be contained in the water-in-oil (W / O type) emulsified composition of the present invention, for example, one or a plurality of ingredients selected from heparinoids, vitamin Es, and the like. Can be used.
本発明のこの態様においてヘパリン類似物質という場合、血液凝固阻害作用を有する「ヘパリン」と類似の構造または類似の作用を有する物質のことで、物質的には多硫酸化コンドロイチン硫酸と呼ばれる物質である。本発明においては、特に、日本薬局方外医薬品規格に収載されている「ヘパリン類似物質」に適合するムコ多糖多硫酸エステルを使用することができる。本発明の油中水型(W/O型)乳化組成物中における、ヘパリン類似物質の含有量は、例えば、全体の0.01〜5.0質量%、好ましくは0.05〜1.0質量%、さらに好ましくは0.1〜0.5質量%とすることができる。 In this aspect of the present invention, the term heparinoid refers to a substance having a structure or an action similar to that of "heparin" having a blood coagulation inhibitory action, and is a substance physically called polysulfated chondroitin sulfate. .. In the present invention, in particular, a mucopolysaccharide polysulfate ester conforming to the "heparin-like substance" listed in the Japanese Pharmacopoeia Non-Pharmaceutical Standards can be used. The content of the heparinoid in the water-in-oil (W / O type) emulsified composition of the present invention is, for example, 0.01 to 5.0% by mass, preferably 0.05 to 1.0% by mass, and more preferably 0.1 to 0.1 to the total content. It can be 0.5% by mass.
本発明のこの態様においてビタミンE類という場合、トコフェロール、およびその誘導体(例えば、酢酸トコフェロール、コハク酸トコフェロールカルシウム等)を使用することができる。 When referring to vitamin Es in this aspect of the present invention, tocopherol and its derivatives (for example, tocopherol acetate, calcium tocopherol succinate, etc.) can be used.
本発明の油中水型(W/O型)乳化組成物中における、ビタミンE類の含有量は、例えば、0.001〜5.0質量%、好ましくは0.05〜3.0質量%、さらに好ましくは0.5〜2.0質量%とすることができる。例えば、処方例として、ビタミンE類を、トコフェロール酢酸エステルとして、0.5%の配合とする場合などが考えられる。 The content of vitamin E in the water-in-oil (W / O type) emulsified composition of the present invention is, for example, 0.001 to 5.0% by mass, preferably 0.05 to 3.0% by mass, and more preferably 0.5 to 2.0% by mass. Can be%. For example, as a prescription example, a case where vitamin Es are blended as tocopherol acetate in 0.5% can be considered.
本発明の油中水型(W/O型)乳化組成物は、皮膚外用塗布経路で用いることができる。したがって、本発明はまた、パンテノールまたはパンテノール類縁物質を有効成分として含有する油中水型(W/O型)乳化組成物から構成される皮膚外用塗布剤を提供する。 The water-in-oil (W / O type) emulsified composition of the present invention can be used in an external application route for skin. Therefore, the present invention also provides a skin external coating agent composed of a water-in-oil (W / O type) emulsified composition containing panthenol or a panthenol-related substance as an active ingredient.
本発明の皮膚外用塗布剤は、油中水型(W/O型)乳化組成物であることから、クリーム剤または乳剤として提供するものである。このようなクリーム剤または乳剤は、当該技術分野において一般的に知られている調製方法に従って調製することができる。また、その調製方法は、特に制限されるものではなく、例えば各種剤型の製剤を調製するのに必要な公知の賦形剤などの適宜成分を上記必須成分及び任意成分と共に配合して各製剤の常法によって調製することができる。 Since the external coating agent for skin of the present invention is a water-in-oil (W / O type) emulsified composition, it is provided as a cream or an emulsion. Such creams or emulsions can be prepared according to preparation methods generally known in the art. The preparation method is not particularly limited, and for example, appropriate components such as known excipients necessary for preparing preparations of various dosage forms are blended together with the above essential components and optional components to prepare each preparation. It can be prepared by the conventional method of.
本発明の皮膚外用塗布剤には、パンテノールまたはパンテノール類縁物質、追加の成分として配合されていてもよいヘパリン類似物質(例えば、多硫酸化コンドロイチン硫酸)やビタミンE類(例えば、トコフェロール酢酸エステル)に加えて、さらにその他必要に応じて本発明の効果を損なわない限りにおいて、医薬品、医薬部外品及び化粧品等に使用される様々な有効成分を配合してもよい。そのようなさらなる追加の有効成分としては、例えば、抗炎症剤、抗ヒスタミン剤、生薬成分、鎮痒剤、創傷治癒剤、局所麻酔剤、ビタミン剤、清涼化剤、保湿剤、殺菌剤、血管収縮剤及びアミノ酸類等を含有させることができる。 The external coating agent for skin of the present invention includes panthenol or a panthenol-related substance, a heparinoid substance (for example, polysulfated chondroitin sulfate) which may be added as an additional component, and vitamin Es (for example, tocopherol acetate). ), And if necessary, various active ingredients used in pharmaceuticals, quasi-drugs, cosmetics, etc. may be blended as long as the effects of the present invention are not impaired. Such additional active ingredients include, for example, anti-inflammatory agents, antihistamines, herbal ingredients, antipruritic agents, wound healing agents, local anesthetics, vitamins, refreshing agents, moisturizers, fungicides, vasoconstrictors and Amino acids and the like can be contained.
以下、実施例及び比較例を示し、本発明を具体的に説明するが、本発明は下記実施例に制限されるものではない。 Hereinafter, the present invention will be specifically described with reference to Examples and Comparative Examples, but the present invention is not limited to the following Examples.
実施例1:パンテノールを含有する油中水型クリーム
本実施例においては、パンテノールを油中水型クリームとした場合と水中油型クリームとした場合とで、皮膚の水分含有量がどのように変化するかを明らかにすることを目的として、実験を行なった。
Example 1: Water-in-oil cream containing panthenol In this example, what is the water content of the skin depending on whether the panthenol is a water-in-oil cream or an oil-in-water cream. An experiment was conducted with the aim of clarifying whether it changes to.
本実施例においては、パンテノールを油中水型クリームとした場合(製造例1)と水中油型クリームとした場合(比較例2)とを、パンテノールを含まない油中水型クリーム(比較例1)および水中油型クリーム(比較例3)と比較した。それぞれの製剤例のA成分(油相成分)およびB成分(水相成分)の具体的成分は、下記の表1に示す通りである。 In this example, the case where panthenol is used as a water-in-oil cream (Production Example 1) and the case where panthenol is used as an oil-in-water cream (Comparative Example 2) are compared with a water-in-oil cream containing no panthenol (comparison). It was compared with Example 1) and oil-in-water cream (Comparative Example 3). The specific components of the A component (oil phase component) and the B component (aqueous phase component) of each formulation example are as shown in Table 1 below.
それぞれの製造例および比較例は、A成分およびB成分をそれぞれ70〜80℃で加温溶解した。そして、撹拌しながらA成分にB成分を徐々に加えて乳化した後、撹拌しながら冷却してクリーム剤を得た。 In each of the production examples and comparative examples, the components A and B were respectively heated and dissolved at 70 to 80 ° C. Then, component B was gradually added to component A while stirring to emulsify, and then cooled while stirring to obtain a cream.
次に、ヒト被験者(男性および女性、年齢は26〜35歳の範囲)の前腕内側部の皮膚を、消毒用エタノールを含ませたガーゼで拭き、乾燥させ、この前腕内側部に直径2 cmの円形の印を付し、測定部位とした。 Next, the skin on the medial forearm of human subjects (male and female, ages ranging from 26 to 35 years) was wiped with gauze soaked in ethanol for disinfection, dried, and the medial forearm was 2 cm in diameter. A circular mark was added to mark the measurement site.
測定部位の角層水分量は、表皮角層水分量測定装置SKICON-200EX(I.B.S Co., Ltd製)で測定した。クリーム剤塗布前、およびクリーム剤を塗布して1時間後に、測定部位の角層水分量をこの装置により測定した。 The water content of the stratum corneum at the measurement site was measured with the epidermal stratum corneum water content measuring device SKICON-200EX (manufactured by I.B.S Co., Ltd.). Before applying the cream agent and 1 hour after applying the cream agent, the water content of the stratum corneum at the measurement site was measured by this device.
クリーム剤塗布前の測定値と、クリーム剤塗布1時間後の測定値より、角層水分量の変化率(%)を以下の計算式に従って算出した:
角層水分量の変化率(%)=(1時間後の測定値)/(塗布前の測定値)×100。
From the measured value before applying the cream and the measured value 1 hour after applying the cream, the rate of change (%) in the water content of the stratum corneum was calculated according to the following formula:
Rate of change in water content in the stratum corneum (%) = (measured value after 1 hour) / (measured value before application) x 100.
結果を図1に示す。クリーム剤を塗布しない無処置群を「対照」とした。グラフの値はそれぞれ、各群の6例の平均値、エラーバーは標準誤差を示す。 The results are shown in Figure 1. The untreated group to which no cream was applied was designated as "control". The values in the graph are the average values of the 6 cases in each group, and the error bars indicate the standard error.
製造例1のとおり、パンテノールを含有する油中水型クリームの塗布により、対照(無処置群)及び比較例1(パンテノールを含有しない油中水型クリーム)と比較して、角層水分量は顕著に増加し、その差は明確であった。 As shown in Production Example 1, by applying the water-in-oil cream containing panthenol, the stratum corneum moisture was compared with the control (untreated group) and Comparative Example 1 (water-in-oil cream not containing panthenol). The amount increased significantly and the difference was clear.
他方、比較例2及び比較例3に示すとおり、水中油型クリームでは、パンテノールの有無によって、角層水分量の変化に大きな差は認められなかった。 On the other hand, as shown in Comparative Example 2 and Comparative Example 3, in the oil-in-water cream, no significant difference was observed in the change in the water content of the stratum corneum depending on the presence or absence of panthenol.
実施例2:油中水型クリーム中のパンテノール含有量による効果
本実施例においては、様々な量のパンテノールを含む油中水型クリームを作製した場合に、皮膚の水分含有量がどのように変化するかを明らかにすることを目的として、実験を行なった。
Example 2: Effect of panthenol content in water-in-oil cream In this example, what is the water content of the skin when water-in-oil cream containing various amounts of panthenol is prepared? An experiment was conducted with the aim of clarifying whether it changes to.
本実施例においては、0.5%〜4%までのパンテノールを油中水型クリームとした場合(製造例3〜6)とパンテノールを含まない油中水型クリーム(比較例1)と比較した。それぞれの製剤例のA成分(油相成分)およびB成分(水相成分)の具体的成分は、下記の表2に示す通りである。 In this example, the case where 0.5% to 4% of panthenol was used as the water-in-oil cream (Production Examples 3 to 6) was compared with the water-in-oil cream containing no panthenol (Comparative Example 1). .. The specific components of the A component (oil phase component) and B component (aqueous phase component) of each formulation example are as shown in Table 2 below.
それぞれの製造例および比較例は、A成分およびB成分をそれぞれ70〜80℃で加温溶解した。そして、撹拌しながらA成分にB成分を徐々に加えて乳化した後、撹拌しながら冷却してクリーム剤を得た。 In each of the production examples and comparative examples, the components A and B were respectively heated and dissolved at 70 to 80 ° C. Then, component B was gradually added to component A while stirring to emulsify, and then cooled while stirring to obtain a cream.
実施例1と同様の手順で、各群8例ずつのヒト被験体からデータを取得し、実施例1と同様の手順で角層水分の変化率についての結果を得た。結果を図2に示す。図2においても、クリーム剤を塗布しない無処置群を「対照」とした。グラフの値はそれぞれ、各群の8例の平均値、エラーバーは標準誤差を示す。 Data were obtained from 8 human subjects in each group by the same procedure as in Example 1, and the results on the rate of change in stratum corneum water were obtained by the same procedure as in Example 1. The result is shown in figure 2. Also in FIG. 2, the untreated group to which the cream agent was not applied was designated as the “control”. The values in the graph are the average values of the eight cases in each group, and the error bars indicate the standard error.
製造例3〜6のとおり、パンテノールを含有する油中水型クリームの塗布により、0.5%〜4%までのパンテノールの添加量によらず、対照(無処置群)及び比較例1(パンテノールを含有しない油中水型クリーム)と比較して、角層水分量は顕著に増加し、その差は明確であった。 As shown in Production Examples 3 to 6, by applying the water-in-oil cream containing panthenol, control (untreated group) and Comparative Example 1 (bread) regardless of the amount of panthenol added from 0.5% to 4%. The water content of the stratum corneum was significantly increased as compared with the water-in-oil cream containing no tenor, and the difference was clear.
実施例3:パンテノールおよび追加の成分を含有する油中水型クリーム
本実施例においては、パンテノールを追加の成分とともに油中水型クリームとした場合に、皮膚の水分含有量がどのように変化するかを明らかにすることを目的として、実験を行なった。
Example 3: Water-in-oil cream containing panthenol and additional ingredients In this example, how the water content of the skin is when panthenol is made into a water-in-oil cream with additional ingredients. Experiments were conducted with the aim of clarifying whether it would change.
本実施例においては、パンテノールを、追加の成分として多硫酸化コンドロイチン硫酸およびトコフェロール酢酸エステルとともに含有した油中水型クリームとした場合(製造例2)と、パンテノールを含まないが多硫酸化コンドロイチン硫酸を含むもの(比較例4)、トコフェロール酢酸エステルを含むもの(比較例5)、または多硫酸化コンドロイチン硫酸とトコフェロール酢酸エステルとを両方含むもの(比較例6)と比較した。それぞれの製剤例のA成分(油相成分)およびB成分(水相成分)の具体的成分は、下記の表3に示す通りである。 In this example, in the case of a water-in-oil cream containing pantenol together with polysulfated chondroitin sulfate and tocopherol acetate as additional components (Production Example 2), pantenol is not included but is sulfated. Comparison was made with those containing chondroitin sulfate (Comparative Example 4), those containing tocopherol acetate (Comparative Example 5), or those containing both sulfated chondroitin sulfate and tocopherol acetate (Comparative Example 6). The specific components of the A component (oil phase component) and the B component (aqueous phase component) of each formulation example are as shown in Table 3 below.
それぞれの製造例および比較例は、A成分およびB成分をそれぞれ70〜80℃で加温溶解した。そして、撹拌しながらA成分にB成分を徐々に加えて乳化した後、撹拌しながら冷却してクリーム剤を得た。 In each of the production examples and comparative examples, the components A and B were respectively heated and dissolved at 70 to 80 ° C. Then, component B was gradually added to component A while stirring to emulsify, and then cooled while stirring to obtain a cream.
多硫酸化コンドロイチン硫酸として、日本薬局方外医薬品規格「ヘパリン類似物質」に適合するものを使用した。 As the polysulfated chondroitin sulfate, a substance conforming to the Japanese Pharmacopoeia non-Japanese drug standard "heparinoid" was used.
実施例1と同様の手順で、各群6例ずつのヒト被験体からデータを取得し、実施例1と同様の手順で角層水分の変化率についての結果を得た。結果を図3(A)および(B)に示す。図3(A)および(B)どちらにおいても、クリーム剤を塗布しない無処置群を「対照」とした。グラフの値はそれぞれ、各群の6例の平均値、エラーバーは標準誤差を示す。 Data were obtained from 6 human subjects in each group by the same procedure as in Example 1, and the results on the rate of change in stratum corneum water were obtained by the same procedure as in Example 1. The results are shown in FIGS. 3 (A) and 3 (B). In both FIGS. 3 (A) and 3 (B), the untreated group to which no cream was applied was designated as the "control". The values in the graph are the average values of the 6 cases in each group, and the error bars indicate the standard error.
製造例2のとおり、パンテノールを多硫酸化コンドロイチン硫酸及びトコフェロール酢酸エステルと併用した油中水型クリームの場合にも、パンテノールは優れた保湿効果を発揮した。この併用の効果は、多硫酸化コンドロイチン硫酸を含有するがパンテノールやトコフェロール酢酸エステルを含まない油中水型クリームの保湿効果(比較例4)や、トコフェロール酢酸エステルを含有するがパンテノールや多硫酸化コンドロイチン硫酸を含まない油中水型クリーム(比較例5)の保湿効果、多硫酸化コンドロイチン硫酸およびトコフェロール酢酸エステルを含有するがパンテノールを含まない油中水型クリーム(比較例6)の保湿効果よりも高い効果が得られた。 As shown in Production Example 2, panthenol also exhibited an excellent moisturizing effect in the case of a water-in-oil cream in which panthenol was used in combination with polysulfated chondroitin sulfate and tocopherol acetate. The effects of this combination include the moisturizing effect of a water-in-oil cream containing polysulfated chondroitin sulfate but not panthenol or tocopherol acetate (Comparative Example 4), or the effect of panthenol or polyus containing tocopherol acetate Moisturizing effect of water-in-oil cream containing sulfated chondroitin sulfate (Comparative Example 5), water-in-oil cream containing polysulfated chondroitin sulfate and tocopherol acetate but not panthenol (Comparative Example 6) A higher effect than the moisturizing effect was obtained.
パンテノールを油中水型(W/O型)乳化組成物に含有させた場合、これを皮膚に塗布した場合に、短時間でパンテノールによる優れた保湿効果を発揮することができた。さらに、油中水型乳化組成物とすることにより、保湿や肌荒れ改善を目的に使用されるヘパリン類似物質及びビタミンE類と併用した場合にも、パンテノールは優れた保湿効果は発揮することができた。 When panthenol was contained in a water-in-oil (W / O type) emulsified composition, when it was applied to the skin, the excellent moisturizing effect of panthenol could be exhibited in a short time. Furthermore, by using a water-in-oil emulsified composition, panthenol can exert an excellent moisturizing effect even when used in combination with heparinoids and vitamin E used for the purpose of moisturizing and improving rough skin. did it.
Claims (8)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019053730 | 2019-03-20 | ||
JP2019053730 | 2019-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2020158493A true JP2020158493A (en) | 2020-10-01 |
Family
ID=72641810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020047463A Pending JP2020158493A (en) | 2019-03-20 | 2020-03-18 | Water-in-oil type (w/o type) cream containing panthenol |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2020158493A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022139742A1 (en) * | 2020-12-21 | 2022-06-30 | Eczacibasi Tuketim Urunleri Sanayi Ve Ticaret Anonim Sirketi | Skin care product strengthening the skin structure |
-
2020
- 2020-03-18 JP JP2020047463A patent/JP2020158493A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022139742A1 (en) * | 2020-12-21 | 2022-06-30 | Eczacibasi Tuketim Urunleri Sanayi Ve Ticaret Anonim Sirketi | Skin care product strengthening the skin structure |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2537235C2 (en) | Mildly acting indelible compositions for skin care | |
JP4549006B2 (en) | Gel ointment | |
MXPA04000002A (en) | Agent containing fat (oil), which contains onion extract, the production and use thereof for caring, preventing or treating damaged skin tissue, especially scarred tissue. | |
JP5052558B2 (en) | Gel ointment | |
WO2008047680A1 (en) | External preparation for skin | |
JP7421558B2 (en) | Semi-solid oily pharmaceutical composition containing pirfenidone applied to tissue repair | |
JP2005060234A (en) | External preparation for skin | |
JP6753312B2 (en) | Topical skin preparation for medical use | |
JP2020158493A (en) | Water-in-oil type (w/o type) cream containing panthenol | |
DK2306999T3 (en) | Compositions for the treatment of rosacea comprising chitosan and a dicarboxylsyreamid | |
JPH0899889A (en) | Therapeutic agent for atopic dermatitis | |
AU2015213569B2 (en) | Topical formulations of Heparin | |
JP2005519935A (en) | Compositions and methods for the delivery of dermatological cosmetics | |
JP5338030B2 (en) | Adapalene-containing external preparation composition | |
WO2004091489A2 (en) | Topical blood pressure composition | |
JP2018203674A (en) | Sebum secretion promoter and external composition | |
EP4164585A1 (en) | A hydroalcoholic gel and a method of manufacturing said gel | |
JP7312527B2 (en) | emulsion composition | |
WO2023120583A1 (en) | External composition for acne, and external composition for acne bacterium-selective antimicrobial/sterilization | |
JP2000204046A (en) | External medicine | |
JP6084579B2 (en) | Oil-in-water cream composition containing tacrolimus | |
JP5980171B2 (en) | Adapalene-containing external preparation composition | |
JP2001163777A (en) | Skin lotion | |
WO2022131079A1 (en) | Topical composition | |
JP2023018775A (en) | external composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240229 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240531 |